Lucid Capital analyst Alex Fuhrman initiated coverage of ASP Isotopes (ASPI) with a Buy rating and $15 price target The company is “entering a phase of rapid growth” as it transitions to commercial production of isotopes with the potential to transform a wide range of high-tech industries, the analyst tells investors in a research note. The firm sees ASP as well positioned to help reduce the West’s dependence on Russian isotope supplies critical to medicine and nuclear power.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASPI:
- ASP Isotopes Inc call volume above normal and directionally bullish
- ASP Isotopes subsidiary completes purchase of certain assets from One 30 Seven
- Largest borrow rate increases among liquid names
- Unusually active option classes on open October 15th
- Morning Movers: BofA, Morgan Stanley jump following Q3 results